Skip to main content
AmigoFish

The Uromigos

The UromigosAudio

Format:
Podcast
New episodes:
Daily
Typical length:
about 40 minutes
Latest episode:
Not rated yet

About this show

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Covers: oncology, genitourinary cancer, renal cell carcinoma, prostate cancer, bladder cancer, antibody drug conjugates, cancer immunotherapy, circulating tumor dna

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

The Uromigos is a podcast on the latest developments in genitourinary cancer, hosted by Brian Rini and Tom Powles. Recent episodes cover T cell engagers in kidney cancer, doublet therapy in renal cell carcinoma, prostate cancer sequencing, and antibody drug conjugates and ctDNA in bladder cancer.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)

    · 35 min

    Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

    Not rated yet
  • Episode 498: APCCC 2026 - mCRPC

    · 21 min

    This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.

    Not rated yet
  • Episode 497: Reflections on the capivasertib ODAC

    · 21 min

    This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.

    Not rated yet
  • Episode 496: APCCC 2026 - mHSPC Landscape

    · 26 min

    Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.

    Not rated yet
  • Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer

    · 31 min

    This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.

    Not rated yet
  • Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist

    · 40 min

    Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.

    Not rated yet
  • Episode 493: The Role of Chemotherapy in mHSPC

    · 47 min

    In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting definitions of disease volume, and the implications for treatment decisions.

    Not rated yet
  • Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors

    · 33 min

    This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.

    Not rated yet
  • Episode 490: Systemic Therapy Only in Patients wtih MIBC

    · 48 min

    Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients

    Not rated yet
  • Episode 489: Live Podcast From EAU

    · 48 min

    Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.

    Not rated yet